SR604, developed by Shanghai RAAS Blood Products Co., Ltd., is currently undergoing a Phase II clinical trial targeting von Willebrand disease (VWD), a prevalent bleeding disorder. The trial aims to establish the drug's efficacy, safety, and pharmacokinetic profile. The global market for VWD treatments is expanding, with increasing awareness and diagnosis rates. Competitive products include existing therapies such as DDAVP and plasma-derived VWF preparations. Successful outcomes from this trial could position SR604 as a significant player in the VWD treatment landscape, potentially capturing market share from established therapies. The trial's recruitment across multiple centers in China indicates a robust operational strategy, but the company must navigate regulatory pathways and market access challenges to ensure commercial viability.